Assessment of the antineoplastic potential of chalcones in animal models

Current Medicinal Chemistry

Volumn 20, Issue 2, 2013, Pages 186-221

  Roman, B I ^a,c   Heugebaert, T S A ^a,c   Bracke, M E ^b   Stevens, C V ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Angiogenesis; Animal Models; Antitumor Agents; Cancer; Cell Cycle; Chalcones; Chemoprevention; Cytotoxicity; In Vivo; Invasion; Metastasis; Mitosis; Natural Products; Phytochemicals; Xenograft Experiments

Indexed keywords

2',4' DIHYDROXY 6' METHOXY 3',5' DIMETHYLCHALCONE; 4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; 4' (PARA TOLUENESULFONAMIDO) 4 HYDROXYCHALCONE; 4' ACETAMIDO 4 HYDROXYCHALCONE; 4' PARA AMINOPHENYLSULFONAMIDO; 4' PARA METHOXYPHENYLSULFONAMIDO; ANGELICA KEISKEI EXTRACT; ANTINEOPLASTIC AGENT; CHALCONE; CHALCONE DERIVATIVE; CLEISTOCALYX OPERCULATUS EXTRACT; DOXORUBICIN; FLAVOKAWAIN A; FLAVOKAWAIN B; FLAVOKAWAIN C; FLAVONOID; GLYCYRRHIZA GLABRA EXTRACT; HELICHRYSUM MARACANDICUM EXTRACT; HUMULUS LUPULUS EXTRACT; ISOLIQUIRITIGENIN; KAVA EXTRACT; LONCHOCARPUS NEUROSCAPHA EXTRACT; LOPHIRA ALATA EXTRACT; PLANT EXTRACT; RUSCUS ACULEATUS EXTRACT; SAFFLOWER EXTRACT; SOFALCONE; SORAFENIB; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOANGELOL; XANTHOHUMOL;

A J MOUSE; ANGELICA KEISKEI; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BAGG ALBINO MOUSE; BDF1 MOUSE; BLADDER CANCER; BLADDER CARCINOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; C57BL X DBAFF1 MOUSE; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CD 1 MOUSE; CHEMOPROPHYLAXIS; CHEMOSENSITIZATION; CLEISTOCALYX OPERCULATUS; COLON CARCINOGENESIS; DDY MOUSE; DRUG POTENCY; DRUG TARGETING; EXPERIMENTAL MODEL; FISCHER 344 RAT; HELICHRYSUM MARACANDICUM; INSTITUTE FOR CANCER RESEARCH MOUSE; LEUKEMIA; LIVER CANCER; LIVER CARCINOGENESIS; LONCHOCARPUS NEUROSCAPHA; LOPHIRA ALATA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG METASTASIS; LYMPHOMA; MEDICINAL PLANT; MOUSE STRAIN; NASOPHARYNX CANCER; NONHUMAN; NUDE MOUSE; OVARY CANCER; PROSTATE CANCER; REVIEW; SARCOMA; SCID MOUSE; SENSITIVE TO CARCINOGENESIS MOUSE; SKH 1 MOUSE; SKIN CANCER; SKIN CARCINOGENESIS; SPRAGUE DAWLEY RAT; STOMACH CANCER; SWISS ALBINO MOUSE; SWISS WEBSTER MOUSE; UTERUS CANCER; WHITE MOUSE;

EID: 84877960947     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986713804806630     Document Type: Review

References (90)

1. Roman, B.I.; De Ryck, T.; Dierickx, L.; Vanhoecke, B.W.A.; Katritzky, A.R.; Bracke, M.E.; Stevens, C.V. Exploration of the SAR of anti-invasive chalcones: synthesis and biological evaluation of conformationally restricted analogues. Bioorg. Med. Chem., 2012, 20, 4812-4819
2. WHO, Traditional medicine, Fact sheet N134, 2008
3. Fabricant, D.S.; Farnsworth, N.R. The value of plants used in traditional medicine for drug discovery. Environ. Health Persp., 2001, 109, 69-75 (Pubitemid 32303231)
4. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70, 461-477 (Pubitemid 46595760)
5. Reichert, J.M.; Wenger, J.B. Development trends for new cancer therapeutics and vaccines. Drug Disc. Today, 2008, 13, 30-37
6. Results from a search on 'chalcone' resp. 'chalcone' and 'cancer' in Scifinder (web edition), CAS, American Chemical Society, 2011
7. For general reviews of the biological activities of chalcones, consult: (a) Dhar, D.N. The chemistry of chalcones and related compounds, Wiley-Interscience: New York, 1981
8. Dimmock, J.R.; Elias, D.W.; Beazely, M.A.; Kandepu, N.M. Bioactivities of chalcones. Curr. Med. Chem., 1999, 6, 1125-1149
9. Go, M.L.; Wu, X. and Liu, X.L. Chalcones: an update on cytotoxic and chemoprotective properties. Curr. Med. Chem., 2005, 12, 483-499 (Pubitemid 40305634)
10. Fiorentino Gomez, S.; Cifuentes Barreto, M.C.; Hernandez Montao, J.F.; Santander Gonzalez, S.P.; Uruea Pinzon, C.P.; Castaeda Uvajoa, D.M. Bioactive fraction of Petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer. WO 2011/039629 A2, 2011
11. Cvoro, A.; Paruthiyil, S.; Jones, J.O. ; Tzagarakis-Foster, C.; Clegg, N.J.; Tatomer, D.; Medina, R.T.; Tagliaferri, M.; Schaufele, F.; Scanlan, T.S.; Diamond, M.I.; Cohen, I.; Leitman, D.C. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology, 2007, 148, 538-547 (Pubitemid 46150775)
12. Voskoglou-Nomikos, T.; Pater, J.L.; Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res., 2003, 9, 4227-4239 (Pubitemid 37204044)
13. Gerhäuser, C. Beer constituents as potential cancer chemopreventive agents. Eur. J. Canc., 2005, 41, 1941-1954 (Pubitemid 41557680)
14. Lawrence, N.J.; Hadfield, J.A.; McGown, A.T.; Butler, J.; Ducki, S. Combretastatin A-4 derivatives having antineoplastic activity. WO 03/040077 A1, 2003
15. Zhu, X.-F.; Xie, B.-F.; Zhou, J.-M.; Feng, G.-K.; Liu, Z.-C.; Wei, X.-Y.; Zhang, F.-X.; Liu M.-F.; Zeng, Y.-X. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine. Mol. Pharmacol., 2005, 67, 1444-1450 (Pubitemid 40594143)
16. Srinivasan, B.; Johnson, T.E.; Lad R.; Xing, C. Structure-Activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxy chalcone and its analogues as potent nuclear factor B inhibitors and their anticancer activities. J. Med. Chem., 2009, 52, 7228-7235
17. Qian, G.; Ye, C.L.; Wei, D.Z.; Lu Y.H.; Yang, S.L. In vitro and in vivo reversal of cancer cell multidrug resistance by 2',4'-dihydroxy-6'-methoxy-3', 5'-dimethylchalcone. J. Chemother., 2005, 17, 309-314 (Pubitemid 40992270)
18. Ye, C.-L.; Liu, J.-W.; Wei, D.-Z.; Lu Y.-H.; F. Qian, In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model. Cancer Chemother. Pharmacol., 2005, 56, 70-74 (Pubitemid 41201758)
19. Park, K.H.; Lee, J.W.; Ryu, Y.B.; Ryu H.W.; Lee, S.-A. Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds. WO 2008/069608 A1, 2008
20. Lee, S.-A.; Ryu, H.W.; Kim, Y.M.; Choi, S.; Lee, M.J.; Kwak, T.K.; Kim, H.J.; Cho, M.; Park, K.H.; Lee, J.W. Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative. Hepatology, 2009, 49, 1316-1325
21. Lee, S.-A.; Lee, M.-S.; Ryu, H.W.; Kwak, T.K.; Kim, H.; Kang, M.; Jung, O.; Kim, H.J.; Park, K.H.; Lee, J.W. Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. Cancer Biol. Ther., 2011, 11, 330-336
22. Xi, S.; Zhang, Q.; Xie, H.; Liu, L.; Liu, C.; Gao, X.; Zhang, J.; Wu, L.; Qian, L.; Deng, X. [Effects of hydroxy safflor yellow A on blood vessel and mRNA expression with VEGF and bFGF of transplantation tumor with gastric adenocarcinoma cell line BGC-823 in nude mice]. Zhongguo Zhong Yao Za Zhi., 2009, 34, 605-610 [Article written in Chinese]
23. Tang, Y.; Xuesen, L.; Liu, Z.; Simoneau, A.R.; Xie, J.; Zi, X. Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int. J. Cancer, 2010, 127, 1758-1768
24. Rodrigues, J.; Abramjuk, C.; Vásquez, L.; Gamboa, N.; Domínguez, J.; Nitzsche, B.; Höpfner, M.; Georgieva, R.; Bäumler, H.; Stephan, C.; Jung, K.; Lein, M.; Rabien, A. New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. Pharm. Res., 2011, 28, 907-919
25. Zi, X.; Simoneau, A.R. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of bax proteindependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res., 2005, 65, 3479-3486 (Pubitemid 40524635)
26. Tang, Y.; Simoneau, A.R.; Xie, J.; Shahandeh, B.; Zi, X. Effets of the kava chalcone flavokawain a differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev. Res., 2008, 1, 439-451
27. Sunkara, S.P.; Edwards, M.L.; Stemerick, D.M. Controlling the growth of certain tumor tissue with chalcone derivatives. US Patent 4,904,697, 1990
28. Sasayama, T.; Tanaka, K.; Mizukawa, K.; Kawamura, A.; Kondoh, T.; Hosoda, K.; Kohmura, E. Trans-4-Iodo,4'-boranyl-chalcone induces antitumor activity against malignant glioma cell lines in vitro and in vivo. J. Neurooncol., 2007, 85, 123-132 (Pubitemid 47629394)
29. Ku, B.M.; Ryu, H.W.; Lee, Y.K.; Ryu, J.; Jeong, J.Y.; Choi, J.; Cho, H.J.; Park, K.H.; Kang, S.S. 4'-Acetoamido-4-hydroxychalcone, a chalcone derivative, inhibits glioma growth and invasion through regulation of the tropomyosin 1 gene. Biochem. Biophys. Res. Comm., 2010, 402, 525-530
30. Albini, A.; Dell'Eva, R.; Vené, R.; Ferrari, N.; Buhler, D.R.; Noonan, D.M.; Fassina, G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-B and Akt as targets. Faseb J., 2006, 20, 527-529 (Pubitemid 46671238)
31. Kato, R.; Nakadate, A.; Yamamoto, S. [Lipoxygenase inhibition and tumor promotor inhibition by medicinal plant components.] Wakan Iyaku Gakkaishi, 1985, 2, 162-163 [article written in Japanese]
32. Aizu, E.; Nakadate, T.; Yamamoto, S.; Kato R. Inhibition of 12-Otetradecanoylphorbol-13-Acetate-mediated epidermal ornithine decarboxylase induction and skin tumor promotion by new lipoxygenase inhibitors lacking protein kinase C inhibitory effects. Carcinogenesis, 1986, 7, 1809-1812
33. Nakadate, T.; Yamamoto, S.; Aizu, E.; Kato, R. Inhibition by lipoxygenase inhibitors of 7-bromomethylbenz[a]anthracene-caused epidermal ornithine decarboxylase induction and skin tumor promotion in mice. Carcinogenesis, 1989, 10, 2053-2057 (Pubitemid 19280485)
34. Yamamoto, S. ;Aizu, E.; Jiang, H.; Nakadate, T.; Kiyoto, I.; Wang J.C.; Kato, R. The potent anti-tumor-promoting agent isoliquiritigenin. Carcino genesis, 1991, 12, 317-323
35. Okuyama, T.; Takata, M.; Takayasu, J.; Hasegawa, T.; Tokuda, H.; Nishino, A.; Nishino, H.; Iwashima, A. Anti-tumor-promotion by principles obtained from Angelica keiskei. Planta Med., 1991, 57, 242-246
36. Shibata, S.; Inoue, H.; Iwata, S.; Ma, R.; Yu, L.; Ueyama, H.; Takayasu, J.; Hasegawa, T.; Tokuda, H.; Nishino, A.; Nishino, H.; Iwashima, A. Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflate root on inflammatory ear edema and tumour promotion in mice. Planta Med., 1991, 57, 221-224
37. Murakami, A.; Tanaka, S.; Ohigashi, H.; Hirota, M.; Irie, R.; Takeda, N.; Tatematsu, A.; Koshimizu, K. Chalcone tetramers, lophirachalcone and alatachalcone, from Lophira alata as possible anti-tumor promoters. Biosci. Biotech. Biochem., 1992, 56, 769-772
38. Satomi, Y. Inhibitory effects of 3'-methyl-3-hydroxy-chalcone on proliferation of human malignant tumor cells and on skin carcinogenesis. Int. J. Cancer, 1993, 55, 506-514 (Pubitemid 23300606)
39. Shibata, S. Anti-tumorigenic chalcones. Stem Cells, 1994, 12, 44-52 (Pubitemid 24045785)
40. Ramanathan, R.; Das, N.P.; Tan, C.H. Inhibition of tumor promotion and cell proliferation by plant polyphenols. Phytother. Res., 1994, 8, 293-296 (Pubitemid 24269747)
41. Huang, M.-T.; Liu, Y.; Xie, J.-G.; Newmark, H.H.; Ho, C.-T. Protective effect of dibenzoylmethane on chemically-And uv light-induced skin, inflammation, sunburn lesions, and skin carcinogenesis in mice. In Food Factors in Health Promotion and Disease Prevention, ACS Symposium Series, 2003, 851, Chapter 17, p. 196
42. Akihisa, T.; Tokuda, H.; Hasegawa, D.; Ukiya, M.; Kimura, Y.; Enjo, F.; Suzuki, T.; Nishino, H. Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects. J. Nat. Prod., 2006, 69, 38-42 (Pubitemid 43241751)
43. Yagura, T.; Motomiya, T.; Ito, M.; Honda, G.; Iida, A.; Kiuchi, F.; Tokuda, H.; Nishino, H. Anticarcinogenic compounds in the Uzbek medicinal plant, Helicrysum maracandicum. J. Nat. Med., 2008, 62, 174-178
44. Kabiev, O.K.; Vermenichev, S.M. Kinetic characteristics of the antineoplastic activity of chalcones on Ehrlich's ascetic sarcoma. Izv. Akad. Nauk Kaz. SSR, Ser. Biol., 1971, 9, 72-75
45. De Méllo, J.F.; De Lima, O.G.; De Albuquerque, M.M.F.; Battista, G.; Marini-Bettólo, G.B.; De Andrade Lyra, F.D.; Da Silva, E.C.; De Barros Coélho e Lizete, J.S.; De Oliveira, L. Chalconas O-e C-preniladas com antividades antibiótica e antineoplástica, isoladas de Lonchocarpus neuroscapha Benth. Rev. Inst. Antibiot. (Recife), 1974, 14, 39-50
46. Markaverich, B.M.; Gregory, R.R.; Alejandro, M.; Kittrell, F.S.; Medina, D.; Clark, J.H.; Varma, M.; Varma, R.S. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res., 1990, 50, 1470-1478 (Pubitemid 20090457)
47. Markaverich, B.; Gregory, R.; Varma, R.S.; Varma, M.; Clark, J.; Waldrep, J.C. Growth inhibitors and methods of treating cancer and cell proliferative diseases. WO 91/17749, 1991
48. Markaverich, B.M.; Medina, D.; Clark, J.H. Effects of combination estrogen: cyclophosphamide treatment on the growth of the MXT transplantable mammary tumor in the mouse. Cancer Res., 1983, 43, 3208-3211 (Pubitemid 13061574)
49. Markaverich, B.M.; Varma, R.S. Combination therapy using bioflavonoid compounds with anti-cancer drugs. WO 93/01824, 1993
50. Anto, R.J.; Kuttan, G.; Kuttan, R.; Sathyanarayana, K.; Rao, M.N.A. Tumorreducing and antioxidant activities of sydnone-substituted chalcones. J. Clin. Biochem. Nutr., 1994, 17, 73-80 (Pubitemid 2156497)
51. Wattenberg, L.W.; Coccia, J.B.; Galbraith, A.R. Inhibition of carcinogeninduced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure. Cancer Lett., 1994, 83, 165-169 (Pubitemid 24253533)
52. Lou, Y.-R.; Lu, Y.-P.; Xie, J.-G.; Zhu, B.T.; Thomas, P.E.; Newmark, H.L.; Haung, M.-T. Inhibitory effect of dibenzoylmethane (DBM) on 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumorigenesis in rodents. Proc. Am. Assoc. Cancer Res., 1999, 40, 652
53. Lin, C.-C.; Lu, Y.-P.; Lou, Y.-R.; Ho, C.-T.; Newmark, H.H.; MacDonald, C.; Singelatary, K.W.; Huang, M.-T. Inhibition by dietary dibenzoylmethane of mammary gland proliferation, formation of DMBA-DNA adducts in mammary glands, and mammary tumorigenesis in Sencar mice. Cancer Lett., 2001, 168, 125-132 (Pubitemid 32524273)
54. Huang, M.-T.; Lou, Y.-R.; Xie, J.G.; Ma, W.; Lu, Y.-P.; Yen, P.; Zhu, B.T.; Newmark, H.; Ho, C.-T. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethyulbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis, 1998, 19, 1697-1700 (Pubitemid 28441876)
55. Cuendet, M.; Oteham, C.P.; Moon, R.C.; Pezzuto, J.M. Quinone reductase induction as a biomarker for cancer chemoprevention. J. Nat. Prod., 2006, 69, 460-463
56. Cuendet, M.; Guo, J.; Luo, Y.; Chen, S.; Oteham, C.P.; Moon, R.C.; van Breemen, R.B.; Marler, L.E.; Pezzuto, J.M. Cancer chemopreventive activity and metabolism of isoliquiritigenin, a compound found in licorice. Cancer Prev. Res., 2010, 3, 221-232
57. Cabrera, M.; Lavaggi, M.L.; Croce, F.; Celano, L.; Thomson, L.; Fernández, M.; Pintos, C.; Raymondo, S.; Bollati, M.; Monge, A.; de Ceráin, A.L.; Piro, O.E.; Cerecetto, H.; González, M. Identification of chalcones as in vivo liver monofunctional phase II enzymes inducers. Bioorg. Med. Chem., 2010, 18, 5391-5399
58. Baba, M.; Asano, R.; Takigami, I.; Takahashi, T.; Ohmura, M.; Okada, Y.; Sugimoto, H.; Arika, T.; Nishino, H.; Okuyama, T. Studies on cancer Chemoprevention by Traditional Folk Medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol. Pharm. Bull., 2002, 25, 247-250 (Pubitemid 39592115)
59. Kohno, H.; Yamaguchi, K.; Taima, M.; Tanaka, T. Prevention of colonic aberrant crypt foci by dietary feeding of chalcone and 2-hydroxychalcone in male F344 rats. J. Toxicol. Pathol., 2002, 15, 137-143
60. Mailliet, P.; Combeau, C.; Bissery, M.-C.; Cherrier, M.-P.; Caulfield, T.; Tiraboschi, G. 1,3-diarylprop-2-en-1-ones, compositions containing same and use thereof. WO 03/048106 A2, 2003
61. Takahashi, T.; Takasuka, N.; Iigo, M.; Baba, M.; Nishino, H.; Tsuda, H.; Okuyama, T. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci. 2004, 95, 448-453 (Pubitemid 38832690)
62. Sale, S.; Tunstall, R.G.; Ruparelia, K.C.; Butler, P.C.; Potter, G.A.; Steward, W.P.; Gescher, A.J. Effects of the potential chemopreventive agent DMU-135 on adenoma development in the ApcMinmouse. Invest. New Drugs, 2006, 24, 459-464 (Pubitemid 44273020)
63. Chin, Y.-W.; Jung, H.-A.; Liu, Y.; Su, B.-N.; Castoro, J.A.; Keller, W.J.; Pereira, M.A.; Kinghorn, A.D. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J. Agric. Food Chem., 2007, 55, 4691-4697 (Pubitemid 46960894)
64. Edwards, M.L.; Stemerick, D.M.; Sumkara, P.S. Chalcones: a new class of antimitotic agents. J. Med. Chem., 1990, 33, 1948-1954 (Pubitemid 20228984)
65. Makita, H.; Tanaka, T.; Fujitsuka, H.; Tatematsu, N.; Satoh, K.; Hara, A.; Mori, H. Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercitin. Cancer Res., 1996, 56, 4904-4909 (Pubitemid 26374427)
66. Denda, A.; Kitayama, W.; Puatanachokchai, R.; Tsutsumi, M.; Konishi, Y.; Kuniyasu, H.; Baba, M.; Okuyama, T.; Nishino, H. Effects of isoliquirithigenin on the development of preneoplastic liver lesions caused by a cholinedeficient, l-Amino acid-defined diet and on the urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats. J. Toxicol. Pathol., 2003, 16, 201-207
67. Nam, N.-H.; Kim, Y.; You, Y.-J.; Hong, D.-H.; Kim, H.-M.; Ahn, B.-Z. Cytotoxic 2',5'-dihydroxychalcones with unexpected antiangiogenic activity. Eur. J. Med. Chem., 2003, 38, 179-187 (Pubitemid 36288472)
68. Kimura, Y.; Baba, K. Antitumor and antimetastatic activities of Angelica keiskei roots, part 1: isolation of an active substance, xanthoangelol. Int. J. Cancer, 2003, 106, 429-437 (Pubitemid 36870408)
69. Kimura, Y.; Taniguchi, M.; Baba, K. Antitumor and antimetastatic activities of 4-hydroxyderricin isolated from Angelica keiskei roots. Planta Med., 2004, 70, 211-219 (Pubitemid 38445186)
70. Lee, Y.S.; Lim, S.S.; Shin, K.H.; Kim, Y.S.; Ohuchi, K.; Jung, S.H. Antiangiogenic and anti-tumor activities of 2'-hydroxy-4'-methoxychalcone. Biol. Pharm. Bull., 2006, 29, 1028-1031
71. Johnson, T.E. Flavokawains A and B: Chemopreventive constituents of kava against lung tumorigenesis. Poster presented at the 236th ACS National Meeting, Devision of Medicinal Chemistry, Philadelphia, USA, 2008
72. Johnson, T.E.; Hermanson, D.; Wang, L.; Kassie, F.; Upadhyaya, P.; O'Sullivan, M.G.; Hecht, S.S.; Lu, J.; Xing, C. Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. Am. J. Chinese Med., 2011, 39, 727-742
73. Yamazaki, S.; Morita, T.; Endo, H.; Hamamoto, T.; Baba, M.; Joichi, Y.; Kaneko, S.; Okada, Y.; Okuyama, T.; Nishino, H.; Tokue, A. Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. Cancer Lett., 2002, 183, 23-30 (Pubitemid 34607348)
74. Kamei, H.; Koide, T.; Kojimam, T.; Hasegawa, M.; Terabe, K.; Umeda, T.; Hashimoto, Y. Flavonoid-mediated tumor growth suppression demonstrated by in vivo study. Cancer Biother. Radio., 1996, 11, 193-196 (Pubitemid 26279401)
75. Kamei, H.; Koide, T.; Hashimoto, Y.; Kojima, T.; Hasegawa, M. Tumor cell growth suppression by chalcone (1,3-diphenyl-2-propen-1-one). Cancer Biother. Radio., 1997, 12, 51-54 (Pubitemid 27150031)
76. Shi, H.-B.; Zhang, S.-J.; Ge, Q.-F.; Guo, D.-W.; Cai, C.-M.; Hu, W.-X. Synthesis and anticancer evaluation of thiazolyl-chalcones. Bioorg. Med. Chem. Lett., 2010, 20, 6555-6559
77. Boumendjel, A.; McLeer-Florin, A.; Champelovier, P.; Allegro, D.; Muhammad, D.; Souard, F.; Derouazi, M.; Peyrot, V.; Toussaint, B.; Boutonnat, J. A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models. BMC Cancer, 2009, 9, 242-252
78. Perjési, P.; Bayer, Z.; Ember I. Effect of E-2-(4'- methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[a]anthracene- induced onco/ suppressor gene action in vivo I: a 24-hour experiment. Anticancer Res., 2000, 20, 475-482
79. Perjési, P.; Gyöngyi, Z.; Z. Bayer Effect of E-2-(4'-methoxybenzylidene)-1-benzosuberone on the 7,12-dimethylbenz[a] anthracene-induced onco/ suppressor gene action in vivo II: a 48-hour experiment. Anticancer Res., 2000, 20, 1839-1848 (Pubitemid 30628210)
80. Steiner, G.G. The correlation between cancer incidence and kava consumption. Hawaii Med. J., 2000, 59, 420-422
81. Teschke, R.; Schwarzenboeck, A.; Hennermann, K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol., 2008, 20, 1182-1193
82. Johnson, T.E.; Kassie, F.; O'Sullivan, M.G.; Negia, M.; Hanson, T.E.; Upadhyaya, P.; Ruvolo, P.P.; Hecht, S.S.; Xing, C. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a] pyrene-induced lung tumorigenesis in A/J mice. Cancer Prev. Res., 2008, 1, 430-438
83. Dimmock, J.R.; Kandepu, N.M.; Nazarali, A.J.; Kowalchuk, T.P.; Motaganahalli, N.; Quail, J.W.; Mykytiuk, P.A.; Audette, G.F.; Prasad, L.; Perjési, P.; Allen, T.M.; Santos, C.L.; Szydlowski, J.; De Clercq, E.; Balzarini, J. Conformational and quantitative structure-Activity relationship study of cytotoxic 2-Arylidenebenzocycloalkanones. J. Med. Chem., 1999, 42, 1358-1366 (Pubitemid 29200871)
84. Neilsen, A.T.; Houlihan, W.J. The aldol condensation. Org. React., 2011, 16, 1-438
85. Boumendjel, A.; Boccard, J.; Carrupt, P.A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Materaj, E.L.; Dumontet, C. Antimitotic and antiproliferative activities of chalcones: forward structure-Activity relationship. J. Med. Chem., 2008, 51, 2307-2310 (Pubitemid 351503287)
86. Chaffer, C.L.; Weinberg, R.A. A perspective on cancer cell metastasis. Science, 2011, 331, 1559-1564
87. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, Maryland, USA, 2005
88. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. Faseb J., 2007, 22, 659-661
89. Woodward, E.J.; Twelves, C. Scheduling of taxanes: a review. Curr. Clin. Pharmacol., 2010, 5, 226-231
90. Ni, L.; Meng, C.Q.; Sikorski, J.A. Recent advances in therapeutic chalcones. Expert Opin. Ther. Patents, 2004, 14, 1669-1691 (Pubitemid 39625100)